Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by equities researchers at Morgan Stanley from an "overweight" rating to an "equal weight" rating in a research report issued on Friday.
https://www.marketbeat.com/instant-alerts/nasdaq-jazz-a-buy-or-sell-right-now-2021-01/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.